South Dakota Investment Council - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 201 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q2 2019. The put-call ratio across all filers is 1.09 and the average weighting 0.3%.

Quarter-by-quarter ownership
South Dakota Investment Council ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q1 2021$159,000
-6.5%
6,8900.0%0.00%0.0%
Q4 2020$170,000
-40.6%
6,8900.0%0.00%
-50.0%
Q3 2020$286,000
-13.3%
6,8900.0%0.01%
-25.0%
Q2 2020$330,000
-24.0%
6,8900.0%0.01%
-33.3%
Q1 2020$434,000
-49.2%
6,8900.0%0.01%
-33.3%
Q4 2019$854,000
+38.4%
6,890
-25.9%
0.02%
+50.0%
Q3 2019$617,000
-16.6%
9,3000.0%0.01%
-20.0%
Q2 2019$740,000
-65.0%
9,300
-50.8%
0.02%
-66.7%
Q1 2019$2,114,000
-59.3%
18,900
-57.9%
0.04%
-26.2%
Q4 2018$5,190,000
+58.0%
44,900
+72.7%
0.06%
-14.1%
Q3 2018$3,285,000
+36.9%
26,000
-9.1%
0.07%
+36.5%
Q2 2018$2,400,000
-14.4%
28,600
-37.3%
0.05%
-18.8%
Q1 2018$2,805,000
+5.3%
45,6000.0%0.06%
+8.5%
Q4 2017$2,664,000
+7.7%
45,600
+7.0%
0.06%
+18.0%
Q3 2017$2,473,000
-52.1%
42,6000.0%0.05%
-54.1%
Q2 2017$5,158,000
+7.1%
42,6000.0%0.11%
+11.2%
Q1 2017$4,818,000
-0.1%
42,600
-4.1%
0.10%
-3.9%
Q4 2016$4,824,000
-34.0%
44,4000.0%0.10%
-32.5%
Q3 2016$7,308,000
+15.4%
44,4000.0%0.15%
+8.6%
Q2 2016$6,335,000
+2.7%
44,400
-7.5%
0.14%
+3.0%
Q1 2016$6,167,000
+14.1%
48,000
+32.6%
0.14%
+14.4%
Q4 2015$5,406,000
-3.9%
36,200
+6.8%
0.12%
-8.5%
Q3 2015$5,623,000
-27.7%
33,900
+5.3%
0.13%
-17.3%
Q2 2015$7,772,000
-18.2%
32,200
-4.5%
0.16%
-14.3%
Q1 2015$9,504,000
+54.2%
33,700
-14.7%
0.18%
+50.4%
Q4 2014$6,162,00039,5000.12%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q2 2019
NameSharesValueWeighting ↓
Chicago Capital Management, LLC 185,781$4,611,56512.16%
Samsara BioCapital, LLC 640,688$11,878,3563.64%
ALPINE ASSOCIATES MANAGEMENT INC. 2,203,295$40,849,0892.14%
Versor Investments LP 378,480$7,017,0191.42%
Magnetar Financial LLC 2,407,209$44,629,6551.14%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,077,893$38,524,1360.85%
Fort Baker Capital Management LP 430,600$7,983,3240.74%
EHP Funds Inc. 84,210$1,561,2530.73%
Terrapin Asset Management, LLC 30,000$556,2000.63%
AQR Arbitrage LLC 734,970$13,626,3440.61%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders